KRSA
Korsana Biosciences, Inc.Healthcare · $149M market cap
Verdict
We can't put a fair value on KRSA right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow KRSA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 9, 2026: no open-market purchases and 4 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
About Korsana Biosciences, Inc.
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works